Clinical Report: Chinese Physicians' Knowledge of Vonoprazan for H. pylori and GERD

Overview

This study evaluates the awareness and clinical application of vonoprazan among Chinese physicians for treating H. pylori infection and GERD. Findings indicate a need for improved education and guideline adherence to enhance patient outcomes.

Background

Helicobacter pylori infection and gastroesophageal reflux disease (GERD) are prevalent health issues in China, with significant morbidity and healthcare costs. Current treatment regimens, primarily involving proton pump inhibitors (PPIs), often face challenges such as suboptimal adherence and antibiotic resistance. The introduction of vonoprazan, a potassium-competitive acid blocker, presents a potential alternative that may improve treatment efficacy and patient compliance.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• 42.8% prevalence of H. pylori infection and 10.6% for GERD in China.
• Current guidelines recommend bismuth quadruple therapy and high-dose dual therapy for H. pylori treatment.
• Vonoprazan shows promise for H. pylori eradication and PPI-refractory GERD.
• Physicians' awareness and attitudes towards vonoprazan's efficacy and safety are critical for its adoption.
• Barriers to vonoprazan's clinical utilization include cost and lack of familiarity among physicians.

Clinical Implications

Enhancing physician education on vonoprazan could improve adherence to treatment guidelines and patient outcomes. Addressing perceived barriers to its use is essential for integrating this therapy into clinical practice.

Conclusion

The study highlights the need for increased awareness and education regarding vonoprazan among Chinese physicians to optimize treatment for H. pylori infection and GERD.

References

1. Journal of Gastroenterology, Comprehensive Review and Network Meta-Analysis, 2019 -- Comparative Efficacy of Vonoprazan Versus Proton-Pump Inhibitors in Long-Term Management of Gastroesophageal Reflux Disease
2. Journal of Gastroenterology, Global Approaches to H. pylori Eradication Therapy, 2017 -- Strategies for Preventing Gastric Cancer through Test-and-Treat Protocols
3. Journal of Gastroenterology, Updated Evidence-Based Guidelines for the Management of Peptic Ulcer Disease, 2020
4. The New Gastroenterologist, AGA Clinical Practice Update, 2025 -- The Role of P-CABs in Cases of PPI Treatment Failure
5. ACG GUIDELINE, 2024 -- ACG H. pylori Guidelines Highlights
6. Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China, PMC
7. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection, PubMed
8. Efficacy and safety of vonoprazan-amoxicillin dual therapy, PubMed
9. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis, PubMed
10. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers, ScienceDirect
11. ACG GUIDELINE
12. Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis - PMC
13. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial - PubMed
14. Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis - PubMed
15. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial - PubMed
16. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review - ScienceDirect